The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -6,400 | -5,600 |
| Stock-based compensation | 685 | 1,734 |
| Issuance of share capital for payments in kind | 0 | 27 |
| Depreciation and amortization | - | 0 |
| Accretion of debt issuance costs on notes payable and notes payable, related party | 93 | - |
| Gain on settlement of current liabilities | 774 | 1,244 |
| Loss on debt extinguishment | -967 | - |
| Change in fair value of warrant liabilities | 253 | 80 |
| Impairment loss on other intangible assets | 5,180 | - |
| Loss on derivative liability | -100 | - |
| Deferred tax benefit | -1,088 | - |
| Unrealized foreign currency exchange (gains) losses | 56 | 394 |
| Prepaid expenses and other current assets | -129 | -263 |
| Accounts payable and accrued expenses | -704 | -112 |
| Net cash used in operating activities | -2,121 | -5,406 |
| Proceeds from issuance of shares, net of issuance costs | 0 | 5,879 |
| Proceeds from issuance of notes payable | 2,099 | - |
| Proceeds from employee vesting of restricted shares | 0 | 33 |
| Proceeds from pre-funded warrants | 0 | 330 |
| Repayments of notes payable | -33 | -455 |
| Proceeds from issuance of convertible notes | - | 0 |
| Payments on short-term financing arrangement | 169 | 273 |
| Net cash provided by financing activities | 1,897 | 5,514 |
| Effect of exchange rates on cash | -3 | 4 |
| Net change in cash | -227 | 112 |
| Cash and cash equivalents at beginning of period | 2,659 | - |
| Cash and cash equivalents at end of period | 2,544 | - |
Akari Therapeutics Plc (AKTX)
Akari Therapeutics Plc (AKTX)